Compare OSPN & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSPN | BNTC |
|---|---|---|
| Founded | 1991 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 449.1M | 420.3M |
| IPO Year | 2000 | 2020 |
| Metric | OSPN | BNTC |
|---|---|---|
| Price | $10.55 | $11.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $16.67 | ★ $27.67 |
| AVG Volume (30 Days) | ★ 550.2K | 183.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.86% | N/A |
| EPS Growth | 28.77 | ★ 80.94 |
| EPS | ★ 1.88 | N/A |
| Revenue | ★ $243,180,000.00 | N/A |
| Revenue This Year | $3.12 | N/A |
| Revenue Next Year | $3.42 | N/A |
| P/E Ratio | $5.69 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.16 | $9.85 |
| 52 Week High | $18.13 | $17.15 |
| Indicator | OSPN | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 40.58 | 51.44 |
| Support Level | $10.26 | $11.30 |
| Resistance Level | $11.68 | $12.75 |
| Average True Range (ATR) | 0.41 | 0.77 |
| MACD | 0.02 | 0.18 |
| Stochastic Oscillator | 31.75 | 45.16 |
OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. Its solutions secure and manage access to digital assets and protect online transactions, via mobile devices and in-person. Authentication and anti-fraud solutions are the organization's primary product offerings and include multifactor authentication and virtual private network access capabilities. The company derives revenues from hardware and license fees, maintenance and support fees, and subscription fees. A large majority of the firm's revenue is generated in Europe, the Middle East, and Africa, and the rest in the United States and Asia-Pacific region.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.